Stocks Health care OGEN
NYSE · Health careOragenics Inc (OGEN)
It posted a net loss of $10.1M. At June 30, 2026 it held $3.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Oragenics Inc
- Net worth
- Oragenics Inc has a market value (market cap) of $1.5M at the latest share price, and shareholders' equity of $3.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $37.7K (-71.4% year on year), with a net loss of $20.7M.
- Cash flow
- In fiscal 2025 operations used $9.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Oragenics Inc's next report was expected around November 6, 2026 and is not on file with the SEC yet.
What Oragenics Inc does
Oragenics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker OGEN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$9.8M | -$4.56 | n/a |
| 2024 | n/a | -$10.6M | -$47.88 | n/a |
| 2023 | $37.7K | -$20.7M | -$274.71 | n/a |
| 2022 | $131.5K | -$14.3M | -$212.77 | -$15.4M |
| 2021 | $87K | -$15.7M | -$4.19 | -$13.5M |
| 2020 | n/a | -$26.4M | -$14.06 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Oragenics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026
- August 28, 2026
- August 13, 2026
- July 6, 2026
- May 20, 2026Additional proxy material DEFA14A
- May 20, 2026Proxy statement DEF 14A
- May 19, 2026
- May 8, 2026Preliminary proxy statement PRE 14A
- May 8, 2026
- May 7, 2026Other event 8-K
Insider trades
What the people running Oragenics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| December 12, 2025 | Telling FredDirector | Sold | 210 | $198.4 |
| December 12, 2025 | Telling FredDirector | Sold | 210 | $198.4 |
Who owns OGEN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Five Narrow Lane LP13G, passive | 9.99% | July 2, 2025 |
| Sabby Management, LLC13G, passive with 2 related filers | 9.9% | January 21, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 948 shares in total, about $323.4 at the last price.
| Holder | Shares |
|---|---|
| Telling FredDirector | 948 |
Questions about OGEN
What does Oragenics Inc do?
Oragenics Inc is a company in the Health care sector, listed on NYSE as OGEN. Its shares trade on NYSE under the ticker OGEN.
What is Oragenics Inc's net worth?
Oragenics Inc has a market value (market cap) of $1.5M at the latest share price, and shareholders' equity of $3.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Oragenics Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $10.1M.
When did Oragenics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 16, 2026.
When is Oragenics Inc's next earnings report?
Oragenics Inc's next report was expected around November 6, 2026 and is not on file with the SEC yet.
Similar companies
Compare OGEN with
Follow OGEN
Get an email when Oragenics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Oragenics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.